Uterine tumor resembling ovarian sex-cord tumor (UTROSCT) is an extremely rare uterine stromal neoplasm of uncertain origin that accounts for less than 0.5% of uterine malignancies. Here, we report, using MRI, 18 F-FDG, and 68 Ga-FAPI-04 PET/CT, the imaging findings for peritoneal metastatic lesions from postoperative UTROSCT in a 58-year-old woman. The peritoneal lesions showed only mild uptake on 18 F-FDG PET/CT. Subsequent 68 Ga-FAPI-04 PET/CT revealed intense tracer uptake in the lesions, indicating the potential value of this modality for detecting recurrence and metastasis in UTROSCT.

Pulmonary sarcomatoid carcinoma (PSC) is a rare and highly aggressive form of non-small cell lung cancer. Rectal metastasis of PSC is an extremely rare condition. We herein report a rare case of PSC accompanied by rectal metastasis detected by 18F-FDG PET/CT. This case highlights the diagnostic value of 18F-FDG PET/CT in detecting uncommon metastatic sites in PSC.

This study aimed to assess and compare the Durie-Salmon PLUS staging performance and high-risk prediction capabilities between [68Ga]Ga-Pentixafor and [18F]FDG PET/CT in newly diagnosed multiple myeloma (NDMM). Eligible participants with NDMM who underwent [68Ga]Ga-Pentixafor and [18F]FDG PET/CT between October 2021 and March 2025 were prospectively enrolled in this study (NCT05255926). The diagnostic and staging performance of [68Ga]Ga-Pentixafor and [18F]FDG were assessed and compared. The parameters including standardized uptake value (SUV), tumor-to-liver ratio (TLR), total bone marrow uptake (TBMU), total bone marrow uptake volume (TBMV), and total burden score (TBS) were calculated. Independent predictors for high-risk NDMM were identified using single-factor and multivariate logistic regression. Sixty-nine participants (40 men) with a median age of 64 years (interquartile range [IQR], 57–71.5 years) were finally analysed. [68Ga]Ga-Pentixafor PET/CT exhibited a higher positive detection rate (82.6

Integrin αvβ6, an epithelial-specific integrin, plays a crucial role in the development and prognosis of multiple tumors and has emerged as a potential target for cancer diagnosis and treatment. The novel integrin αvβ6-targeted radiotracer [68Ga]Ga-Trivehexin shows excellent targeting specificity and favorable tumor-to-background contrast. In this prospective clinical study (NCT05835570) involving 58 participants with non-small cell lung cancer (NSCLC), [68Ga]Ga-Trivehexin and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) showed perfect diagnostic accuracy (100%, 58/58) for the detection of primary tumors. In detecting lymph node metastasis, [68Ga]Ga-Trivehexin exhibited similar diagnostic sensitivity to [18F]FDG PET/CT (80.0% vs 72.0%), with higher specificity (93.8% vs 62.5%, p < 0.001) and accuracy (91.2% vs 64.2%, p < 0.001) in per-station analysis. [68Ga]Ga-Trivehexin outperformed [18F]FDG in detecting brain metastasis (sensitivity, 92.3% vs 38.5%; p = 0.031). Additionally, [68Ga]Ga-Trivehexin PET/CT results changed the therapeutic regimens of 14 (24.1%) participants. The maximum standardized uptake value (SUVmax) and tumor-to-liver parenchyma ratio (TLR) derived from [68Ga]Ga-Trivehexin correlated with integrin β6 expression in NSCLC. Overall, [68Ga]Ga-Trivehexin PET/CT represents an invaluable tool for identifying lymph node and brain metastases and shows comparable diagnostic efficacy in detecting primary tumors and other distant metastases compared with [18F]FDG in NSCLC, potentially guiding treatment decision-making.

We compared 68 Ga-Trivehexin PET/CT imaging with 18 F-FDG in a 49-year-old woman diagnosed with breast cancer. While both imaging modalities detected a soft tissue mass in the central left breast, 68 Ga-Trivehexin PET/CT identified not only the large lesion but also 3 additional tiny foci that were undetected by 18 F-FDG PET/CT. Our report suggested that 68 Ga-Trivehexin PET/CT might offer superior detection efficacy for breast cancer compared with 18 F-FDG PET/CT, highlighting its potential as an alternative imaging agent.

Gallium-68-labelled fibroblast activation protein inhibitor ([68 Ga]Ga-FAPI) is a tumour-stromal imaging agent showing complementary value alongside fluorine-18 fluorodeoxyglucose ([18F]FDG) in cancer imaging. This study investigated the feasibility of a same-day dual-tracer positron emission tomography/computed tomography (PET/CT) protocol with [68 Ga]Ga-FAPI-04 following [18F]FDG in patients presenting with negative or equivocal [18F]FDG. Patients with negative or equivocal [18F]FDG findings underwent dual-tracer PET/CT (named FDG-mixed FAPI PET/CT, abbreviated to mFAPI PET/CT) on the same day, with [68 Ga]Ga-FAPI-04 administered 4.0–7.75 h following [18F]FDG injection. Lesion detection rates and lesion-to-background uptake ratios (LBRs) were compared between [18F]FDG and mFAPI PET/CT. Forty-four patients were included in the analysis. The mFAPI PET was superior to [18F]FDG PET for primary tumour detection (86.2

Abstract A 15-year-old adolescent boy was hospitalized because of abdominal pain. Blood tests indicated inflammation markers were elevated. Fecal occult blood test was weakly positive. CT revealed thickening and edema of the small bowel wall, accompanied by gas density shadows and blurring of fat interstitial spaces. Thus, intestinal perforation and gastrointestinal hemorrhage were suspected. In order to investigate the underlying cause, 99mTc-pertechnetate scintigraphy was performed. A tracer accumulated lesion was presented around the navel, suggestive of heterotopic gastric mucosa. Surprisingly, postoperative pathology confirmed coexistence of heterotopic gastric mucosa, intestinal duplication, and heterotopic pancreas, which was a rare condition.

ABSTRACT:Benign metastasizing leiomyoma (BML) is a rare disease associated with pelvic leiomyoma. We report 18 F-FDG and 68 Ga-FAPI PET/CT findings in a 51-year-old woman with multiple BMLs. The mass in the abdominopelvic cavity and other metastatic lesions showed highly increased 68 Ga-FAPI uptake, whereas uptake of 18 F-FDG in those lesions was low. Our report demonstrates that 68 Ga-FAPI PET/CT showed a different result in detecting BML to 18 F-FDG PET/CT, and 68 Ga-FAPI PET/CT may be a promising method for whole-body evaluate metastases.

Fibroblast activation protein (FAP) is a promising diagnostic and therapeutic target in various solid tumors. This study aimed to assess the diagnostic efficiency of 68Ga-labeled FAP inhibitor (FAPI)-04 PET/CT for detecting lymph node metastasis in non-small cell lung cancer (NSCLC) and to investigate the correlation between tumor 68Ga-FAPI-04 uptake and FAP expression. Methods: We retrospectively enrolled 136 participants with suspected or biopsy-confirmed NSCLC who underwent 68Ga-FAPI-04 PET/CT for initial staging. The diagnostic performance of 68Ga-FAPI-04 for the detection of NSCLC was evaluated. The final histopathology or typical imaging features were used as the reference standard. The SUVmax and SUVmean, 68Ga-FAPI-avid tumor volume (FTV), and total lesion FAP expression (TLF) were measured and calculated. FAP immunostaining of tissue specimens was performed. The correlation between 68Ga-FAPI-04 uptake and FAP expression was assessed using the Spearman correlation coefficient. Results: Ninety-one participants (median age, 65 y [interquartile range, 58-70 y]; 69 men) with NSCLC were finally analyzed. In lesion-based analysis, the diagnostic sensitivity and positive predictive value of 68Ga-FAPI-04 PET/CT for detection of the primary tumor were 96.70% (88/91) and 100% (88/88), respectively. In station-based analysis, the diagnostic sensitivity, specificity, and accuracy for the detection of lymph node metastasis were 72.00% (18/25), 93.10% (108/116), and 89.36% (126/141), respectively. Tumor 68Ga-FAPI-04 uptake (SUVmax, SUVmean, FTV, and TLF) correlated positively with FAP expression (r = 0.470, 0.477, 0.582, and 0.608, respectively; all P ≤ 0.001). The volume parameters FTV and TLF correlated strongly with FAP expression in 31 surgical specimens (r = 0.700 and 0.770, respectively; both P < 0.001). Conclusion: 68Ga-FAPI-04 PET/CT had excellent diagnostic efficiency for detecting lymph node metastasis, and 68Ga-FAPI-04 uptake showed a close association with FAP expression in participants with NSCLC.

To compare the efficacy of [68Ga]Ga-FAPI-04 PET/CT in primary or recurrent tumors and metastatic lesions of epithelial ovarian cancer (EOC) with that of fluorine-18 fluorodeoxyglucose ([18F]F-FDG) PET/CT. Forty-nine patients (median age, 57 years; IQR, 51–66 years) with histologically proven primary or relapsed EOC were enrolled. Participants underwent [18F]F-FDG and [68Ga]Ga-FAPI-04 PET/CT. The detection rate, diagnostic accuracy, semiquantitative parameters, tumor staging, and clinical management of the tracers were compared. The diagnostic performance of [18F]F-FDG and [68Ga]Ga-FAPI-04 PET/CT was evaluated and compared using surgical pathology. Differences between methods regarding the peritoneal cancer index (PCI) using preoperative imaging, surgical PCI, and tumor markers (CA125, HE4) were also assessed regarding peritoneal metastases. Among the 49 patients, 28 had primary EOC; 21 had relapsed EOC. [68Ga]Ga-FAPI-04 PET/CT outperformed [18F]F-FDG PET/CT in detecting peritoneal metastases (96.8

A 67-year-old man, with decades of smoking history, complained of chronic low back pain for over 2 months. Magnetic resonance imaging showed a lytic lesion in the L2 vertebral body where bone metastasis was suspected. Fluorine 18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images revealed a tiny pulmonary nodule measuring 9 mm in the largest diameter, with no FDG uptake (Fig. 1B and C). The maximum intensity projection image showed FDG-avid bone lesion (SUVmax, 6.9) in the L2 vertebral body and mild-to-moderate FDG accumulation in the mediastinal and bilateral hilar lymph nodes (Fig. 1A). Gallium 68(68Ga)-labeled fibroblast activation protein (FAP) inhibitors (FAPI) PET/CT was performed the next day to determine if the nodule was the primary tumor. The imaging showed focal FAPI uptake (SUVmax, 4.8) in the solitary pulmonary nodule and intense uptake (SUVmax, 31.3) in the bone lesion (Fig. 2A–C) without abnormal uptake of any other site. FDG-positive lymph nodes were not visualized and were considered to be reactive lymphadenitis. The patient received CT-guided percutaneous biopsy of the L2 lesion. The pathology and immunohistochemistry revealed it as metastatic adenocarcinoma (TTF-1: positive; Napsin A: positive; Ki-67:10%; Fig. 3A–D). The combination of TTF-1 and Napsin A is the reliable marker for the diagnosis of lung adenocarcinoma (1–3). Therefore, the pulmonary nodule was diagnosed as the primary lung adenocarcinoma combined with the histologic findings and 68Ga-FAPI PET imaging. Then, pyramidectomy and artificial vertebral body implantation were performed because the patient refused a pneumonectomy. Then, stereotactic body radiation therapy was performed for the pulmonary nodule twice without progression in 6 months.

Abstract Pulmonary sclerosing pneumocytoma is a rare benign neoplasm arising from the primitive respiratory epithelium. Here, we report 68Ga-FAPI PET/CT findings of pulmonary sclerosing pneumocytoma in a 55-year-old woman. The images showed a solitary pulmonary mass in the left lower lobe with intense 68Ga-FAPI uptake. Our case illustrates that the sclerosing pneumocytoma should be taken into consideration as one of the differential diagnoses in lung nodules/masses with intense 68Ga-FAPI uptake.

La administración de dosis bajas de rituximab es un protocolo utilizado en diversas enfermedades autoinmunes, que ha demostrado también su eficacia y seguridad para el pénfigo vulgar.Determinar si rituximab a dosis bajas es efectivo para el penfigoide ampolloso (PA).Se trató a los pacientes con PA con un ciclo único de dos infusiones de rituximab de 500 mg con un intervalo de dos semanas. Se monitorizaron los puntos temprano y final tardío.Se incluyeron en el estudio seis pacientes, cinco varones y una mujer, con una edad media de 78,6 años (rango: 65.89) e historia media de PA de 6,7 meses (rango: 2-16). Se observó una respuesta rápida y acusada tras un ciclo único de tratamiento, con un tiempo medio hasta el control de la enfermedad y el final de la fase de consolidación de 1,9 (rango: 1-3) y cuatro semanas (rango: 3-5), respectivamente. Cuatro pacientes lograron un punto final tardío a una media de 15,75 semanas (rango: 13-20). Tres de ellos lograron una remisión parcial sin terapia (dos pacientes) o con terapia mínima (un paciente), logrando uno de ellos la remisión completa sin terapia. A un paciente se le realizó un seguimiento de seis semanas tras la administración de rituximab. El paciente restante sufrió una recaída transcurridas cuatro semanas del tratamiento de rituximab, permaneciendo en remisión completa con terapia mínima. Un paciente manifestó gingivoestomatitis herpética relacionada con rituximab.La administración de dosis bajas de rituximab para PA logró tasas de remisión aceptables y reducción de esteroides, con un mejor perfil de seguridad y un menor coste, en comparación con las dosis estándar. Este estudio piloto sugiere que la administración de bajas dosis de rituximab podría ser una opción terapéutica para el PA.Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.To study whether low-dose rituximab is also effective for bullous pemphigoid.Patients with BP were treated with a single cycle of two infusions of rituximab 500 mg at an interval of 2 weeks. Early and late end points were monitored.Six patients, five males and a female, with a mean age of 78.6 years (range 65–89) and a mean history of BP of 6.7 months (range 2–16) were included. A rapid and marked response was observed after a single cycle of treatment, with a mean time to disease control and to end of consolidation phase of 1.9 (range 1–3), and 4 weeks (range 3–5), respectively. Four patients achieved a late end point at a mean of 15.75 weeks (range 13–20). Three of them achieved partial remission with no therapy (two patients) or with minimal therapy (one patient), and one of them achieved complete remission with no therapy. One patient has 6 weeks of clinical follow-up after rituximab administration. The remaining patient relapsed 4 weeks after the rituximab treatment, and remains in complete remission with more than minimal therapy. One patient had a herpetic gingivostomatitis related to rituximab.Low-dose rituximab for BP achieved acceptable remission rates and steroid-sparing activity, with a better safety profile and a lower cost, compared to standard doses. This pilot study suggests that low-dose rituximab could be a therapeutic option for BP.

Positron emission tomography (PET)/near-infrared fluorescence (NIRF) dual-modal imaging presents an enticing prospect for tumor diagnosis and surgical navigation. In this study, we developed a novel probe IR808-DOTA for tumor-targeted PET/NIRF imaging, image-guided surgery, and photothermal therapy. This construct had better water solubility and pharmacokinetics than IR808 and had similar photophysical properties, tumor targeting ability, and photothermal anticancer effect to IR808. By a simple labeling process, IR808-DOTA was labeled with gallium-68 and applied as a PET probe for tumor imaging in MCF-7 tumor xenografted mice. IR808-DOTA itself acted as an NIRF imaging agent in the following surgery for intraoperative navigation to aid surgeons in the delineation of tumor margins and visualizing sentinel lymph nodes to facilitate a more thorough tumor resection. Irradiation by laser, IR808-DOTA could prominently inhibit tumor growth in MCF-7 subcutaneous tumor model mice by directly ablating tumor cells, inhibiting tumor proliferation, and promoting tumor cell apoptosis. In summary, 68Ga-DOTA-IR808 could enable a convenient and user-friendly workflow for tumor imaging and guided surgery, and therefore, it may have great prospects for clinical translation as a PET/NIRF dual-modal probe.

目的 探讨线上以案例为导向的教学法(case-based learning,CBL)结合教学实际,依托QQ群、腾讯会议和学习通平台在核医学理论教学中的应用效果.方法 选取2020年2—6月武汉大学临床医学专业188名学生作为试验组,以2019年2—6月166名学生作为对照组.试验组采用线上CBL教学法教学,对照组采取线下传统教学方法.同时对两组学生进行问卷调查及教学效果评估.结果 试验组学生的影像图片诊断及理论知识考试成绩高于对照组差异有统计学意义(P＜0.05).试验组学生中CBL教学能激发临床学习兴趣、调动学习兴趣和积极性,差异有统计学意义(P＜0.05).课程内容掌握程度虽仍存在个体差异,但试验组学生认为"基本理解""基本掌握"的认同人数占比高于对照组,差异有统计学意义(P＜0.05).结论 基于线上的CBL教学法在核医学教学过程中能培养学生的学习兴趣,激发学生的学习主动性、积极性、自主性,提高其临床应用能力.